Literature DB >> 30431695

Biological evaluation of some quinoline derivatives with different functional groups as anticancer agents.

Tuğba Kul Köprülü1, Salih Ökten2, Şaban Tekin3, Osman Çakmak4.   

Abstract

Due to a great deal of biological activities, quinoline derivatives have drawn attention for synthesis and biological activities in the search for new anticancer drug development. In this work, a variety of substituted (phenyl, nitro, cyano, N-oxide, and methoxy) quinoline derivatives (3-13) were tested in vitro for their biological activity against cancer cell lines, including rat glioblastoma (C6), human cervical cancer cells (HeLa), and human adenocarcinoma (HT29). 6-Bromo-5-nitroquinoline (4), and 6,8-diphenylquinoline (compound 13) showed the greatest antiproliferative activity as compared with the reference drug, 5-fluorouracil (5-FU), while the other compounds showed low antiproliferative activity. 6-Bromo-5-nitroquinoline (4) possesses lower cytotoxic activity than 5-FU in HT29 cell line. Due to its the apoptotic activity 6-Bromo-5-nitroquinoline (4) has the potential to cause cancer cell death.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  apoptosis; cancer cells; cytotoxic activity; nitroquinoline; phenylquinoline; quinolines

Mesh:

Substances:

Year:  2018        PMID: 30431695     DOI: 10.1002/jbt.22260

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  2 in total

1.  Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.

Authors:  Tuğba Kul Köprülü; Salih Ökten; Vildan Enisoğlu Atalay; Şaban Tekin; Osman Çakmak
Journal:  Med Oncol       Date:  2021-06-19       Impact factor: 3.064

2.  Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking.

Authors:  Carine Santos; Luiz Pimentel; Henayle Canzian; Andressa Oliveira; Floriano Junior; Rafael Dantas; Lucas Hoelz; Debora Marinho; Anna Cunha; Monica Bastos; Nubia Boechat
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.